disulfiram 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
928 97-77-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • disulfiram
  • tetraethylthiram disulfide
A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms (acetaldehyde syndrome). It acts by inhibiting aldehyde dehydrogenase.
  • Molecular weight: 296.52
  • Formula: C10H20N2S4
  • CLOGP: 3.88
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 6.48
  • ALOGS: -4.37
  • ROTB: 7
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.20 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.20 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 24.09 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 80 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Aug. 28, 1951 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psychiatric symptom 117.52 41.14 25 916 4545 50599638
Intentional self-injury 111.25 41.14 33 908 23079 50581104

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Milk-alkali syndrome 124.68 36.88 22 1576 500 29572429
Alcohol intolerance 103.40 36.88 18 1580 377 29572552
Psychiatric symptom 65.98 36.88 18 1580 3166 29569763
Drug abuse 56.04 36.88 41 1557 79842 29493087
Metabolic alkalosis 55.65 36.88 13 1585 1223 29571706
Hypercalcaemia 48.16 36.88 20 1578 12739 29560190
Hypertonia neonatal 45.33 36.88 9 1589 391 29572538
Drug interaction 41.59 36.88 52 1546 197333 29375596
Depressed level of consciousness 37.83 36.88 24 1574 36918 29536011
Sopor 37.45 36.88 16 1582 10918 29562011
Intentional overdose 36.91 36.88 24 1574 38504 29534425

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psychiatric symptom 181.23 33.07 43 2395 6230 64490064
Alcohol intolerance 116.77 33.07 19 2419 379 64495915
Milk-alkali syndrome 114.33 33.07 22 2416 1171 64495123
Intentional self-injury 105.23 33.07 40 2398 29004 64467290
Drug abuse 89.70 33.07 58 2380 132316 64363978
Sopor 60.16 33.07 27 2411 29634 64466660
Off label use 58.20 33.07 93 2345 632713 63863581
Drug interaction 53.69 33.07 67 2371 362016 64134278
Intentional overdose 52.57 33.07 36 2402 89908 64406386
Metabolic alkalosis 45.32 33.07 13 2425 3915 64492379
Hypercalcaemia 37.74 33.07 20 2418 31396 64464898
Psychotic disorder 35.94 33.07 20 2418 34558 64461736
Generalised tonic-clonic seizure 35.91 33.07 21 2417 39836 64456458

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N07BB01 NERVOUS SYSTEM
OTHER NERVOUS SYSTEM DRUGS
DRUGS USED IN ADDICTIVE DISORDERS
Drugs used in alcohol dependence
ATC P03AA04 ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS
ECTOPARASITICIDES, INCL. SCABICIDES
Sulfur containing products
ATC P03AA54 ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS
ECTOPARASITICIDES, INCL. SCABICIDES
Sulfur containing products
FDA MoA N0000000183 Acetyl Aldehyde Dehydrogenase Inhibitors
CHEBI has role CHEBI:24127 fungicides
CHEBI has role CHEBI:35487 aldehyde dehydrogenase (NAD) inhibitors
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:37733 EC 3.1.1.8 inhibitor
CHEBI has role CHEBI:48422 angiogenesis antagonist
CHEBI has role CHEBI:50276 topoisomerase I inhibitors
CHEBI has role CHEBI:68495 Type I cell-death inducers
CHEBI has role CHEBI:73240 NF-kappaB inhibitors
CHEBI has role CHEBI:78444 Alpha-carboxylesterase inhibitor
CHEBI has role CHEBI:173085 ferroptosis inducers
MeSH PA D065086 Acetaldehyde Dehydrogenase Inhibitors
MeSH PA D000427 Alcohol Deterrents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D004791 Enzyme Inhibitors
FDA EPC N0000175679 Aldehyde Dehydrogenase Inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Alcoholism indication 7200002
Cirrhosis of liver contraindication 19943007 DOID:5082
Chronic glomerulonephritis contraindication 20917003
Alcohol intoxication contraindication 25702006
Hypothyroidism contraindication 40930008 DOID:1459
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Nephritis contraindication 52845002 DOID:10952
Coronary arteriosclerosis contraindication 53741008 DOID:3393
Psychotic disorder contraindication 69322001
Diabetes mellitus contraindication 73211009 DOID:9351
Epilepsy contraindication 84757009 DOID:1826
Disease of liver contraindication 235856003 DOID:409
Cognitive Impairment following Traumatic Brain Injury contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Aldehyde dehydrogenase, mitochondrial Enzyme INHIBITOR WOMBAT-PK CHEMBL
Sodium/nucleoside cotransporter 1 Transporter Ki 5.24 DRUG MATRIX
Mu-type opioid receptor GPCR Ki 5.85 DRUG MATRIX
Translocator protein Transporter WOMBAT-PK
D(1A) dopamine receptor GPCR Ki 5.97 DRUG MATRIX
D(2) dopamine receptor GPCR Ki 5.12 DRUG MATRIX
Alpha-2A adrenergic receptor GPCR Ki 5.74 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 4.16 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 4.66 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 5.13 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 5.83 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.43 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 5.43 DRUG MATRIX
Adenosine receptor A3 GPCR Ki 6.70 DRUG MATRIX
D(4) dopamine receptor GPCR Ki 5.96 DRUG MATRIX
Kappa-type opioid receptor GPCR Ki 5.61 DRUG MATRIX
Cytochrome P450 1A2 Enzyme IC50 5.40 DRUG MATRIX
Amine oxidase [flavin-containing] A Enzyme IC50 4.86 DRUG MATRIX
cAMP-specific 3',5'-cyclic phosphodiesterase 4A Enzyme IC50 5.32 DRUG MATRIX
C-C chemokine receptor type 5 GPCR Ki 4.74 DRUG MATRIX
C-X-C chemokine receptor type 2 GPCR Ki 5.38 DRUG MATRIX
C-C chemokine receptor type 2 GPCR Ki 6.02 DRUG MATRIX
Mitogen-activated protein kinase 3 Kinase IC50 5.82 DRUG MATRIX
C-C chemokine receptor type 4 GPCR Ki 5.36 DRUG MATRIX
Monoglyceride lipase Enzyme IC50 5.90 CHEMBL
Protein-lysine 6-oxidase Enzyme IC50 6.50 CHEMBL
Lysine-specific demethylase 5A Enzyme IC50 5 CHEMBL
Lysyl oxidase homolog 3 Enzyme IC50 7.03 CHEMBL
Lysyl oxidase homolog 4 Enzyme IC50 7.23 CHEMBL
Histone-lysine N-methyltransferase EHMT2 Enzyme IC50 6.22 CHEMBL
Histone-lysine N-methyltransferase EHMT1 Enzyme IC50 5.80 CHEMBL
Lysyl oxidase homolog 2 Enzyme IC50 6.82 CHEMBL
Gasdermin-D Unclassified IC50 6.40 CHEMBL
Fructose-1,6-bisphosphatase 1 Enzyme IC50 6.22 CHEMBL
Arachidonate 15-lipoxygenase Enzyme IC50 4.79 DRUG MATRIX
5-hydroxytryptamine receptor 1B GPCR Ki 5.67 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 4.33 DRUG MATRIX
Aldehyde dehydrogenase, mitochondrial Enzyme IC50 4.40 CHEMBL
Bifunctional protein GlmU Enzyme IC50 4.07 CHEMBL
Gasdermin-D Unclassified IC50 6.40 CHEMBL
Carbamate kinase, EC 2.7.2.2 Unclassified IC50 6.22 CHEMBL

External reference:

IDSource
4018494 VUID
N0000146816 NUI
D00131 KEGG_DRUG
3554 RXNORM
4018494 VANDF
C0012772 UMLSCUI
CHEBI:4659 CHEBI
CHEMBL964 ChEMBL_ID
DB00822 DRUGBANK_ID
D004221 MESH_DESCRIPTOR_UI
3117 PUBCHEM_CID
7168 IUPHAR_LIGAND_ID
1781 INN_ID
TR3MLJ1UAI UNII
2848 MMSL
4623 MMSL
d01389 MMSL
000752 NDDF
387212009 SNOMEDCT_US
39516004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Disulfiram HUMAN PRESCRIPTION DRUG LABEL 1 0054-0356 TABLET 250 mg ORAL ANDA 17 sections
Disulfiram HUMAN PRESCRIPTION DRUG LABEL 1 0054-0357 TABLET 500 mg ORAL ANDA 17 sections
Disulfiram HUMAN PRESCRIPTION DRUG LABEL 1 42794-028 TABLET 250 mg ORAL ANDA 17 sections
Disulfiram HUMAN PRESCRIPTION DRUG LABEL 1 42794-029 TABLET 500 mg ORAL ANDA 17 sections
Disulfiram HUMAN PRESCRIPTION DRUG LABEL 1 47781-607 TABLET 250 mg ORAL ANDA 18 sections
Antabuse HUMAN PRESCRIPTION DRUG LABEL 1 54868-5034 TABLET 250 mg ORAL ANDA 18 sections
Disulfiram HUMAN PRESCRIPTION DRUG LABEL 1 60429-196 TABLET 250 mg ORAL ANDA 17 sections
Disulfiram HUMAN PRESCRIPTION DRUG LABEL 1 62135-431 TABLET 250 mg ORAL ANDA 13 sections
Disulfiram HUMAN PRESCRIPTION DRUG LABEL 1 62135-432 TABLET 500 mg ORAL ANDA 13 sections
Disulfiram HUMAN PRESCRIPTION DRUG LABEL 1 64980-171 TABLET 250 mg ORAL ANDA 17 sections
Disulfiram HUMAN PRESCRIPTION DRUG LABEL 1 64980-172 TABLET 500 mg ORAL ANDA 17 sections
Disulfiram HUMAN PRESCRIPTION DRUG LABEL 1 68151-2694 TABLET 250 mg ORAL ANDA 17 sections